Are lipid mediators implicated in the production of pro- and anti-inflammatory cytokines during cardiopulmonary bypass graft with extracorporeal circulation?

Cytokine

Volumn 11, Issue 4, 1999, Pages 301-304

  Denizot, Yves ^a   Feiss, Pierre ^b   Nathan, Nathalie ^b  

^a UNIVERSITY OF LIMOGES   (France)

^b DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

Cardiopulmonary bypass; Cytokines; Inflammation; Lipid mediators

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; APROTININ; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; PROSTACYCLIN; PROSTAGLANDIN E2; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE B2; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD LEVEL; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; EXTRACORPOREAL CIRCULATION; HUMAN; MULTIPLE ORGAN FAILURE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; TIME;

EID: 0033119247     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.1998.0428     Document Type: Article

References (23)

1. Casey LC (1993) Role of cytokines in the pathogenesis of cardiopulmonary-induced multisystem organ failure. Ann Thorac Surg 56:S92-S96.
2. Butler J, Rocker GM, Westaby S (1993) Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 55:552-559.
3. Nathan N, Denizot Y, Cornu E, Jauberteau MO, Chauvreau C, Feiss P (1997) Cytokine and lipid mediator blood concentrations after coronary artery bypass graft. Anesth Analg 85:1240-1246.
4. Faymonville ME, Deby-Dupont G, Larbuisson R, Deby C, Bodson L, Limet R, Lamy M (1986) Prostaglandin E2, prostacyclin, and thromboxane changes during nonpulsatile cardiopulmonary bypass in humans. J Thorac Cardiovasc Surg 91:858-866.
5. Steinberg BM, Grossi EA, Schwartz DS, McLoughlin DE, Aguinaga M, Bizekis C, Greenwald J, Flisser A, Spencer FC, Galloway AC, Colvin SB (1995) Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass. Ann Thorac Surg 60:525-529.
6. Nathan N, Denizot Y, Feiss P, Laskar M, Benveniste J, Arnoux B (1992) Variation of blood paf-acether levels after protamine reversal of heparin in human. Acta Anaesthesiol Scand 36:264-269.
7. Wan S, DeSmet JM, Barvais L, Goldstein M, Vincent JL, LeClerc JL (1996) Myocardium is a major source of proinflammatory cytokines in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 112:806-811.
8. Fujiwara T, Seo N, Murayama T, Hirata S, Kawahito K, Kawakami M (1997) Transient rise in serum cytokines during coronary artery bypass graft surgery. Eur Cytokine Netw 8:61-66.
9. Denizot Y, Lorgeot V, Cornu E, Nathan N (1998) Plasma leukaemia inhibitory factor, interleukin-6 and soluble interleukin-6 receptor levels during cardiopulmonary bypass with extracorporeal circulation. Cytokine 10:303-306.
10. Kawamura T, Wakusawa R, Inada K (1997) Interleukin-10 and interleukin-1 receptor antagonists increase during cardiac surgery. Can J Anaesth 44:38-42.
11. McBride WT, Armstrong MA, Gilliland H, McMurray TJ (1996) The balance of pro and anti-inflammatory cytokines in plasma and bronchoalveolar lavage (BAL) at paediatric cardiac surgery. Cytokine 8:724-729.
12. Bonavida B, Mencia-Huerta JM (1994) Platelet-activating factor and the cytokine network in inflammatory processes. Clin Rev Allergy 12:381-395.
13. 2. J Lipid Mediators 6: 175-181.
14. Claesson HE, Odlander B, Jakobsson PJ (1992) Leukotriene B4 in the immune system. Int J Immunopharmacol 14: 441-449.
15. Denizot Y (1997) Platelet-activating factor: Biosynthesis, biodegradation, actions. In eds F von Bruchhausen and U Walter, Handbook of Experimental Pharmacology No. 126, Springer, Heidelberg, pp. 483-506.
16. Saatvedt K, Lindberg H, Michelsen S, Mollnes TE (1996) Release of interleukin 6 and activation of complement during and after paediatric cardiopulmonary bypass. Effect of autotransfusion of shed mediastinal blood and ultrafiltration. Cytokine 8:417-420.
17. Feuerstein G, Hallenbeck JM (1987) Leukotrienes in health and disease. FASEB J 1:186-192.
18. Nathan N, Cornu E, Denizot Y, Feiss P, Arnoux B (1994) Serum platelet-activating factor acetylhydrolase during coronary artery bypass surgery. J Cardiothor Vase Anesth 8:254-255.
19. Stephens CJ, Graham RM, Yadava OP, Leong LL, Sturm MJ, Taylor RR (1992) Plasma platelet-activating factor degradation and serum lipids after coronary bypass surgery. Cardiovasc Res 26:25-31.
20. Blauhut B, Gross C, Necek S, Doran JE, Späth P, Lundsgaard-Hansen P (1991) Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 101:958-967.
21. Nagaoka H, Innami R, Murayama F, Funakoshi N, Hirooka K, Watanabe M, Satoh M (1991) Effects of aprotinin on prostaglandin metabolism and platelet function in open heart surgery. J Cardiovasc Surg 32:31-37.
22. Miwa M, Miyake T, Yamanaka T, Sugatani J, Suzuki Y, Sakata S, Araki Y, Matsumoto M (1988) Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J Clin Invest 82:1983-1992.
23. Cazenave JP, Benveniste J, Mustard FJ (1979) Aggregation of rabbit platelets by platelet-activating factor is independent of the release reaction and the arachidonate pathway and inhibited by membrane active drugs. Lab Invest 41:275-285.